Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for Iovance Biotherapeutics (IOVA) over the last 8 years, with Sep 2025 value amounting to $904.9 million.

  • Iovance Biotherapeutics' Liabilities and Shareholders Equity was N/A to $904.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year change of. This contributed to the annual value of $910.4 million for FY2024, which is 16.67% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Liabilities and Shareholders Equity stood at $904.9 million, which was down 0.27% from $907.4 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Liabilities and Shareholders Equity's 5-year high stood at $966.7 million during Q1 2025, with a 5-year trough of $757.3 million in Q2 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Liabilities and Shareholders Equity value was $869.8 million (recorded in 2024), while the average stood at $863.8 million.
  • Data for Iovance Biotherapeutics' Liabilities and Shareholders Equity shows a peak YoY climbed of 16.67% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $780.4 million in 2023, then climbed by 16.67% to $910.4 million in 2024, then increased by 11.14% to $904.9 million in 2025.
  • Its last three reported values are $904.9 million in Q3 2025, $907.4 million for Q2 2025, and $966.7 million during Q1 2025.